SavedAdd your journal

Journals / Journal of Neurological Sciences (Turkish) / 2017 / Cilt: 34 - Sayı: 3

Gabapentini Kötüye Kullanan ile Tedavi Amaçlı Kullanan Mahkumlar Arasındaki Sosyo Demografik ve Klinik Değişkenlerin Karşılaştırılması

The Comparison of Socio-Demographic and Clinical Variables of Inmates Using Gabapentin For Medicinal Purposes and Those Abusing The Drug

Faruk CİCEKCİ
Adnan KARAİBRAHİMOGLU
Adem AYDIN
Dincer YUKSEKKAVAS
Ali Ulvi UCA
Pages
242–251
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The inmates who were diagnosed as having drug addiction and substance abuse according to the DSM-IV-TR used gabapentin after entering prison to prevent opioid withdrawal symptoms

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the socio-demographic and clinical data of inmates using gabapentin for medicinal purposes and those abusing the drug.
📊
Key Findings & Data:Methods: The study included inmates of the Konya E-Type Prison who used gabapentin between June 2012 and December 2014 and were admitted to the prison polyclinic.
💡
Conclusion & Impact:Conclusion: The inmates who were diagnosed as having drug addiction and substance abuse according to the DSM-IV-TR used gabapentin after entering prison to prevent opioid withdrawal symptoms
🔬Design:Research Article
📍Scope:2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: To compare the socio-demographic and clinical data of inmates using gabapentin for medicinal purposes and those abusing the drug. Methods: The study included inmates of the Konya E-Type Prison who used gabapentin between June 2012 and December 2014 and were admitted to the prison polyclinic. The participants were divided into two groups; those using gabapentin due to existing symptoms without any labeled indication (Group 1), and those using the medication due to disorders with labeled indications (Group 2). Both groups were investigated in terms of drug addiction, drug abuse, and gabapentin abuse according to the Diagnostic and Statistical Manual-Text Revision (DSM IV-TR). Results: Nearly all inmates (n=21) using gabapentin with off-label indications (Group 1) reported using it due to muscle pain, neuropathic pain, sleep disorder, signs of anxiety, sweating, trembling, and nausea-vomiting, whereas those using gabapentin with labeled indications (Group 2) reported using it because of their diseases, such as diabetic neuropathy and epilepsy. Alcohol/substance abuse was found higher among the first-degree relatives of those using gabapentin with off-label indications (P < 0.001). The rates of substance dependence (n=10) and substance abuse (n=13) were significantly higher in Group 1 than in Group 2 (P < 0.001). Conclusion: The inmates who were diagnosed as having drug addiction and substance abuse according to the DSM-IV-TR used gabapentin after entering prison to prevent opioid withdrawal symptoms

Özet

Amaç: Gabapentini tedavi amaçlı-endikasyonlu kullanan mahkumlar ile kötüye kullanan mahkumlar arasındaki sosyodemoğrafik ve klinik verileri karşılaştırmak. Metod: Bu çalışmaya Haziran 2012-Aralık 2014 yılları arasında Konya E Tipi Cezaevinde kalan, cezaevi polikliniğine başvuran ve ağrı polikiliniğimize sevkedilen gabapentin kullananlar mahkumlar dahil edildi. Gabapentini mevcut şikayetlerinden dolayı endikasyonsuz kullananlar (Grup 1), hastalığa bağlı olarak endikasyonlu kullananlar (Grup 2) DSM IV-TR `ye göre madde bağımlılığı, madde kötüye kullanımı ve gabapentin kötüye kullanımı yönünden araştırıldı. Bulgular: Endikasyonsuz gabapentin kullanan mahkumların (Grup 1) tamamına yakını (n:21) gabapentini kas ağrıları, nöropatik ağrı, uyku bozukluğu, anksiyete belirtileri, terleme, titreme ve bulantı-kusma için kullandığını belirtirken, endikasyonlu olarak gabapentini kullanan mahkumlar (Grup 2) daha çok mevcut hastalıklarının belirtilerini baskılamak için (diyabetik nöropati, ve epilepsi) kullandıkları tespit edilmiştir. Endikasyonsuz kullanan grubun birinci derece yakınlarında alkol/madde kullanımının daha yüksek olduğu belirlenmiştir (P

🔖

Cite This Article

CİCEKCİ, F., KARAİBRAHİMOGLU, A., AYDIN, A., YUKSEKKAVAS, D., UCA, A. U. (2022). Gabapentini Kötüye Kullanan ile Tedavi Amaçlı Kullanan Mahkumlar Arasındaki Sosyo Demografik ve Klinik Değişkenlerin Karşılaştırılması. Journal of Neurological Sciences (Turkish), Cilt: 34 - Sayı: 3, 242–251. https://ajindex.com/articles/564814

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Johanson CE, Balster RL, Henningfield JE, et al. Risk management and post-marketing surveillance fort he abuse of medications acting on the central nervous system: expert panel report. Drug Alcohol Depend 2009;105(Suppl.1):65-71
  2. Del Paggio D. Psychotropic medication abuse in correctional facilities. Bay Area Psychopharmacology Newsletter 2005;8:1-5
  3. Markowitz JS, Finkenbine R, Myrick H, King L, Carson WM. Gabapentin abuse in a cocain user: implications for treatment? Clin Psychopharmacol 1997;17:423-424
  4. Reccoppa L, Malcolm R., Ware M. Gabapentin abuse in inmates with prior history of cocaine dependence. The American Juournal on Addictions 2004;13:321-323
  5. Pittenger C, Desan PH. Gabapentin abuse, and delirium tremens upon gabapentin withdrawal. J Clin Psychiatry 2007;68:483-484
  6. Magnus L. Nonepileptic uses of gabapentin. Epilepsia 1999;40 (Suppl 6):566-572 7. Palmer CM, Pope HG Jr. Antiepileptic drugs. In: Gelder MG, Lopez-Ibor JJ, A nderson N, editors. New Textbook of Psychiatry. Vol. 2, 1st ed. New York: Oxford University Press, 2000;1326-1333
  7. British National Formulary, 2014. Gabapentin. http://www.medicinescomplete.com/mc/bnf/current/ PHP2930-gabapentin.htm q=gabapentin&t=search&ss=text&p=1#_hit (Accessed 1 Apr 2014)
  8. Canadian Agency for Drug and Technologies in Health (CADTH). Abuse and misuse potential of pregabalin: a reviwe of the clinical evidence; Contex and policy issues; 2012 http://dpic.org/sites/default/files/Pregabalin/Abuse_ CADTH_24Apr2012.pdf (Accessed 20 Feb 2014
  9. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropatic pain: a systematic review of controlled and uncontrolled literature. Clin J Pain 2001;17:284-295
  10. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57:451-462
  11. Anton RF, Myric H, Baros AM, et al. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptomps. J Clin Psychopharmacol 2009;29:334-342
  12. Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry 1999a;32:107-109
  13. Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind,placebo-controlled trial. J Clin Psychiatry 2007;68:1691-1700
  14. Myrick H, Henderson S, Brady KT, Malcolm R. Gabapentin in the treatment of cocaine dependence: a case series. J Clin Phychiatry